DFTX
Definium Therapeutics, Inc.
NASDAQ · USHealthcareMedical - Pharmaceuticals
$42.80-3.36%
Price as of Jul 20, 2026
DFTX financials
Definium Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $527.0K | $3.2M | $0.00 |
| Gross profit | $0.00 | -$527.0K | -$3.2M | $0.00 |
| Operating expenses | $166.3M | $103.4M | $90.7M | $66.3M |
| Operating income | -$166.3M | -$103.9M | -$93.9M | -$66.3M |
| Net income | -$183.8M | -$108.7M | -$95.7M | -$56.8M |
| EBITDA | -$178.3M | -$105.9M | -$92.6M | -$52.1M |
| Basic EPS | $-2.06 | $-1.54 | $-2.44 | $-1.53 |
| Diluted EPS | $-2.06 | $-0.15 | $-2.44 | $-1.53 |
| Balance sheet | ||||
| Cash & equivalents | $257.8M | $273.7M | $99.7M | $142.1M |
| Total assets | $440.1M | $302.2M | $124.5M | $170.0M |
| Total liabilities | $107.8M | $60.7M | $46.4M | $19.1M |
| Stockholders’ equity | $332.3M | $241.4M | $78.1M | $150.9M |
| Total debt | $0.00 | $21.9M | $14.1M | $72.0K |
| Net debt | -$257.8M | -$251.9M | -$85.6M | -$142.1M |
| Cash flow | ||||
| Operating cash flow | -$131.6M | -$79.1M | -$64.4M | -$50.1M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$131.6M | -$79.1M | -$64.4M | -$50.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |